Levels of soluble tumor necrosis factor receptor 1 and 2 are associated with survival after ST segment elevation myocardial infarction

Befekadu, Rahel,1968-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Laboratory Medicine, Section for Clinical Immunology and Transfusion Medicine, Örebro University Hospital, 70185, Örebro, Sweden,Cardiovascular Research Centre,Orebro Univ Hosp, Sweden; Orebro Univ, Sweden (författare)

Funding agencies:Örebro University HospitalAFA Insurance
Funding Agencies|orebro University Hospital; AFA Insurance; Region orebro County
The soluble tumor necrosis factor receptors (sTNFR1 and sTNFR2) are suggested to play dual roles on physiological and pathophysiological actions of TNF-α. The aim of this study was to investigate the dynamic changes of these biomarkers in patients with ST-segment elevation myocardial infarction (STEMI). Blood was collected from 165 STEMI patients at admission, 1-3 days and 3 months after percutaneous coronary intervention (PCI) and from 40 healthy blood donors. sTNFR1 and sTNFR2 were measured with ELISA. The plasma levels of both sTNFR1 and sTNFR2 were significantly higher than in healthy donors at all three time points. We found no significant differences in sTNFR1 or sTNFR2 when comparing patients with patent versus occluded culprit vessels, or between patients having a thrombus aspiration or not. Survival analysis was performed comparing patients with levels of biomarkers above and below the median values at that time point. We found significant differences in survival for sTNFR2 in acute samples (p = 0.0151) and for both sTNFR1 and sTNFR2 in samples 1-3 days after PCI (p = 0.0054 and p = 0.0003, respectively). Survival analyses suggest that sTNFR1 or sTNFR2 could be promising markers to predict mortality in STEMI patients after PCI.

Grenegård, Magnus,1963-Örebro universitet,Institutionen för medicinska vetenskaper,Cardiovascular Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden,Orebro Univ, Sweden(Swepub:oru)mgd (författare)
Larsson, AndersUppsala universitet,Institutionen för medicinska vetenskaper,Uppsala Univ, Sweden(Swepub:uu)andlarss (författare)
Christensen, KjeldKarlstad Central Hospital, Karlstad, Sweden; Department of Cardiology, Örebro University Hospital, Örebro, Sweden,Karlstad Cent Hosp, Sweden; Orebro Univ Hosp, Sweden (författare)
Ramström, Sofia,1973-Linköpings universitet,Örebro universitet,Institutionen för medicinska vetenskaper,Department of Clinical Chemistry, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden,Cardiovascular Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden,Avdelningen för klinisk kemi och farmakologi,Medicinska fakulteten,Region Östergötland, Klinisk kemi,Orebro Univ, Sweden(Swepub:liu)sofra86 (författare)
Örebro universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Av författaren/redakt...: Befekadu, Rahel, ...; Grenegård, Magnu ...; Larsson, Anders; Christensen, Kje ...; Ramström, Sofia, ...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Kardiologi

Av lärosätet: Örebro universitet; Uppsala universitet; Linköpings universitet

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.